Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Integral Health Asset Management LLC

Key Points

• Integral Health Asset Management increased its stake in Alnylam by 9.1% in Q3 to 60,000 shares worth $27.36 million, making ALNY 1.9% of the firm's portfolio and its 11th largest holding; institutional investors own about 92.97% of the stock.
• Alnylam's latest quarter missed expectations with $1.25 EPS vs. $1.43 expected and $1.10B revenue vs. $1.16B expected, although revenue grew 84.9% year‑over‑year.
• Company insiders sold 53,923 shares (~$18.07M) in the last quarter (including CEO Yvonne Greenstreet), while analysts collectively rate ALNY a "Moderate Buy" with an average price target of $477.96.

Integral Health Asset Management LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 9.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,000 shares of the biopharmaceutical company's stock after acquiring an additional 5,000 shares during the quarter. Alnylam Pharmaceuticals makes up 1.9% of Integral Health Asset Management LLC's investment portfolio, making the stock its 11th largest position. Integral Health Asset Management LLC's holdings in Alnylam Pharmaceuticals were worth $27,360,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. OFI Invest Asset Management increased its stake in shares of Alnylam Pharmaceuticals by 5.8% during the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company's stock worth $184,000 after purchasing an additional 22 shares in the last quarter. Howard Capital Management Inc. lifted its stake in Alnylam Pharmaceuticals by 2.9% in the 3rd quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company's stock valued at $389,000 after buying an additional 24 shares in the last quarter. Frank Rimerman Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company's stock valued at $570,000 after buying an additional 24 shares in the last quarter. Coastal Bridge Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 2.3% during the 3rd quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company's stock valued at $500,000 after buying an additional 25 shares during the last quarter. Finally, Meridian Financial Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 3.5% during the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company's stock valued at $378,000 after buying an additional 28 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $313.41 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The stock's fifty day simple moving average is $344.35 and its 200-day simple moving average is $410.04. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $41.56 billion, a price-to-earnings ratio of 183.28 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts' consensus estimates of $1.43 by ($0.18). The business had revenue of $1.10 billion during the quarter, compared to analysts' expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. Alnylam Pharmaceuticals's revenue for the quarter was up 84.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.65) EPS. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Weiss Ratings raised Alnylam Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a report on Thursday, January 15th. Canaccord Genuity Group increased their price objective on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a "buy" rating in a research note on Tuesday, February 17th. Freedom Capital upgraded Alnylam Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, February 17th. Needham & Company LLC cut their target price on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a "buy" rating for the company in a research note on Thursday, February 12th. Finally, HC Wainwright restated a "buy" rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $477.96.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 6,799 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $2,227,692.35. Following the completion of the sale, the chief executive officer owned 98,628 shares in the company, valued at $32,315,464.20. The trade was a 6.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Tolga Tanguler sold 1,598 shares of the company's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $523,584.70. Following the transaction, the executive vice president directly owned 36,606 shares of the company's stock, valued at approximately $11,993,955.90. This represents a 4.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 53,923 shares of company stock worth $18,072,087 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.